Related Experiment Video
Updated: Aug 3, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic:
Joel M Gelfand1, April W Armstrong2, Stacie Bell3
1Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Insights
This guidance offers recommendations for managing psoriatic disease during the COVID-19 pandemic, covering treatment impacts, risk reduction, and care optimization for patients with psoriasis and psoriatic arthritis.
Area of Science:
- Immunodermatology
- Rheumatology
- Infectious Diseases
- Public Health
Background:
- Psoriatic disease management presents unique challenges during pandemics.
- The coronavirus disease 2019 (COVID-19) pandemic necessitates updated clinical guidance for chronic conditions.
- Patients with psoriatic disease may have altered risks and require specific care considerations.
Purpose of the Study:
- To develop evidence-based guidance for managing psoriatic disease during the COVID-19 pandemic.
- To address clinical questions regarding COVID-19 risk, outcomes, and treatment optimization for patients with psoriatic disease.
- To provide actionable recommendations for healthcare providers and patients.
Main Methods:
- A multidisciplinary task force (TF) with expertise in dermatology, rheumatology, and infectious diseases was convened.
- A Delphi process was employed to reach consensus on clinical guidance statements.
- Clinical questions were informed by inquiries from the National Psoriasis Foundation (NPF) community.
Main Results:
- Twenty-two guidance statements were approved by the TF.
- All statements achieved agreement, with 9 receiving high consensus and 13 moderate consensus.
- Recommendations cover COVID-19 risk, treatment implications, and patient care strategies.
Conclusions:
- The developed guidance addresses critical aspects of psoriatic disease management during the COVID-19 pandemic.
- Evidence quality for some recommendations is limited, highlighting the need for ongoing research.
- The guidance is intended as a living document, subject to updates as new data emerge.
Objective:
To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.
Study Design:
A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
Results:
The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.
Limitations:
The evidence behind many guidance statements is limited in quality.
Conclusion:
These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Pancreatitis II: Collaborative Care
Assessment:
Peripheral Artery Disease IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management

